Concepedia

Author

James Lindsay

Dana-Farber Cancer InstituteORCID

Also Known As

Afzal, Muhammad Umar, J Lindsay, J. Lindsay, James Lindsay, James R. Lindsay, Juanez T Lindsay, Neal Lindeman

462

Publications

4.7K

Citations

22

H-Index

82

Concepts

All Affiliations

Dana-Farber Cancer InstituteBrigham and Women's HospitalHarvard UniversityMemorial Sloan Kettering Cancer CenterDana-Farber Brigham Cancer Center
JL

About

James Lindsay is an author at Dana-Farber Cancer Institute specializing in medicine, pathology, and immunology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

12

12

829

2

Engineering

4

4

77

3

Natural Sciences

2

2

271

4

Health Sciences

1

1

15

5

Public Health

1

1

23

James Lindsay

×

32

Publications

4.5K

Citations

22

H-Index

YearCitations

AACR Project GENIE: Powering Precision Medicine through an International Consortium

Fabrice André, Mónica Arnedos, Alexander S. Baras,

Cancer Discovery

2017

1.9K

Analysis and Visualization of Longitudinal Genomic and Clinical Data from the AACR Project GENIE Biopharma Collaborative in cBioPortal

Ino de Bruijn, Ritika Kundra, Brooke Mastrogiacomo,

Cancer Research

2023

752

Association of High Tumor Mutation Burden in Non–Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels

Biagio Ricciuti, Xinan Wang, Joao V. Alessi,

JAMA Oncology

2022

356

Genome sequence of an Australian kangaroo, Macropus eugenii, provides insight into the evolution of mammalian reproduction and development

Marilyn B. Renfree, Anthony T. Papenfuss, Janine E. Deakin,

Genome biology

2011

211

SMARCA4 and Other SWItch/Sucrose NonFermentable Family Genomic Alterations in NSCLC: Clinicopathologic Characteristics and Outcomes to Immune Checkpoint Inhibition

Joao V. Alessi, Biagio Ricciuti, Liam F. Spurr,

Journal of Thoracic Oncology

2021

140

Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial

Édouard Louis, Matthieu Resche‐Rigon, David Laharie,

˜The œLancet. Gastroenterology & hepatology

2023

101

A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-Dose or Hypofractionated Radiation for Patients with Metastatic Colorectal Cancer

Arta M. Monjazeb, Anita Giobbie‐Hurder, Ana Lako,

Clinical Cancer Research

2021

98

AACR Project GENIE: 100,000 Cases and Beyond

Trevor J. Pugh, Jonathan L. Bell, Jeffrey P. Bruce,

Cancer Discovery

2022

97

Low peripheral blood derived neutrophil-to-lymphocyte ratio (dNLR) is associated with increased tumor T-cell infiltration and favorable outcomes to first-line pembrolizumab in non-small cell lung cancer

Joao V. Alessi, Biagio Ricciuti, Stephanie Alden,

Journal for ImmunoTherapy of Cancer

2021

94

Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRASG12D-mutated non-small-cell lung cancer

Biagio Ricciuti, Joao V. Alessi, Arielle Elkrief,

Annals of Oncology

2022

93

Page 1